In the Original Investigation by Meyer et al, titled “Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography,” published online January 21, 2020,¹ there were errors in the Abstract, the text of the article, Figures 1 and 2, and in the author affiliations list. In the “Main Outcomes and Measures” section of the Abstract, the first sentence should read “We compared tau-positive vs tau-negative groups as indicated by either modality or demographic and clinical variables, amyloid β–PET burden, and flortaucipir-PET binding across Braak stage–related ROIs.” In the “PET Image Processing” subsection of the Methods, both instances of the S in “FreeSurfer” should be capitalized. In the final sentence of the first paragraph of the CSF Measurements subsection of the Methods, “Cobas” should be capitalized. In Figure 1, the R² value should be 0.26. In Figure 2, panel A should be labeled “APOE ε4 carriers,” panel C should be labeled “Aβ⁺ individuals” and have PET⁻ in superscript in all instances, and the y-axis for panel D should be labeled “Global Florbetapir SUVR.” Finally, in the author affiliations, Dr Pichet Binette’s name should be listed as “Pichet Binette” rather than “Binette.” This article was corrected online.

在梅耶（Meyer）等人的原始调查标题为“使用脑脊液磷酸化Tau和AV1451正电子发射断层扫描的阿尔茨海默氏病生物标记差异的特征”，于2020年¹月21日在线发表，¹摘要中有错误，本文正文如下：图1和2，以及作者从属关系列表中。在摘要的“主要结果和措施”部分中，第一句应为“我们比较了tau阳性与tau阴性的人群，如形态或人口统计学和临床​​变量，淀粉样蛋白β–PET负担和氟罗西吡PET结合Braak阶段相关的ROI。” 在“方法”的“ PET图像处理”小节中，S的两个实例在“ FreeSurfer”中应大写。在“方法”的“ CSF测量”小节第一段的最后一句中，应将“ Cobas”大写。在图1中，R ²值应为0.26。在图2中，面板A应该被标记为“ APOE ε4载体，”图C应该被标记为“Aβ ⁺个体”，并且具有PET ^-在所有情况下标，而y轴为面板d应被标记为“全球Florbetapir SUVR 。” 最后，在作者隶属关系中，Pichet Binette博士的名字应列为“ Pichet Binette”而不是“ Binette”。本文已在线更正。